Anticonvulsant screening program nih

Since its establishment in , the program has made important contributions to the development of several FDA-approved drugs for epilepsy, including felbamate Felbatol , topirimate Topamax , lacosamide Vimpat , retigabine Potiga , cannabidiol Epidiolex and cenobamate Xcopri. Accepted compounds are then evaluated in assays from specific flowcharts such as the drug resistant epilepsy flowchart.

The ETSP provides feedback on results and an assessment of the potential success of each particular compound or compound class. Over the forty year history of the ETSP, the models in use have evolved over time such that new assays have been added to the program and others have been discontinued. The site also describes the specific flow charts currently used for compound evaluation.

Those interested in participating should contact Brian Klein, PhD for more information and to discuss research goals, resources, and timelines. The contribution of early detection in TB contact investigation to improve TB case finding was 8. The early detection in TB contact investigation yielded additional notified cases, especially among children.

A comprehensive education, covering cognitive and psychological aspect, is needed to encourage TB contacts to completely participate in early detection program until their diagnosis is confirmed.

Keywords: Indonesia; Tuberculosis; case finding; contact investigation; early detection. Publication types Research Support, Non-U. New models should more closely replicate clinical epilepsy syndromes, allow testing against known biological targets, and facilitate the development of therapeutics targeting pharmacoresistant epilepsy, disease modification, and specific epilepsy subtypes. Potential options include:. Explore precompetitive and other options for making data on submitted compounds available.

Data on over 30, compounds submitted to the ASP remains largely unavailable for research use due to confidentiality agreements with participants. For example, confidentiality could be time-bounded, or data could be presented in a de-identified form.

In addition, NINDS should explore options for making existing data available to the extent possible, while respecting the need to protect intellectual property. This should include options for reporting screening results for submitted compounds past and future , with a goal to provide transparent and timely information that has utility beyond knowing whether a tested compound ultimately reaches the clinic. Mining these data could provide insights into mechanisms of action and reasons for success or failure in ASP models or in later drug development stages, which could suggest new targets to pursue.

Establish an external advisory body that can oversee changes to the ASP, provide ongoing scientific and strategic guidance, and monitor progress. The current ASP working group could serve as the core of such a body, and new members should be added with appropriate expertise to assess potential new models and assays for the program. NINDS should establish regular scientific meetings between this oversight body and ASP leadership and staff to assess progress, monitor the ongoing value of the program, and discuss future directions.

Develop processes and metrics for tracking program progress. Metrics should allow NINDS and external advisors to monitor program operations and outcomes on an ongoing basis. They should not focus exclusively on operations processing and screening of submitted compounds , but on deliverables such as the outcomes of testing and the usefulness of data generated, whether screening results are positive or negative. These metrics should be built into ASP procedures, reported regularly, and tied to performance evaluations of ASP staff.

The ASP provides a resource for academic and industry investigators from the U. The ASP tests compounds submitted by these investigators in several standardized animal seizure models and provides results and advice on further drug development, while protecting confidentiality and intellectual property rights.

The testing is performed via contract at the University of Utah. NINDS staff also create and maintain a database of chemical structures and test results that is designed to provide insights on structure activity relationships. The Epilepsy Research Benchmarks , which present the goals of the epilepsy research and patient community, provide a broad frame for consideration of the ASP role.

In particular, the working group should note that the goals of the epilepsy community have evolved since the ASP began, with increased emphasis on preventing the development of epilepsy, on treatment of resistant epilepsy, and on co-morbid conditions. Likewise, there have been significant changes in many relevant scientific areas, in drug development technology, and in private sector and NIH supported drug development programs generally.